Adagio Medical seeks vote on up to 1-for-1,000 reverse split
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Adagio Medical Holdings, Inc. (ADGM) is seeking stockholder approval for a charter amendment authorizing a reverse split of its common stock of up to an aggregate 1-for-1,000. If approved, the board could choose the ratio and timing and carry out one or more splits on or before the one-year anniversary of approval; approval would not require the board to act. The stated aim is to meet Nasdaq’s minimum bid-price requirement for continued listing.
The company completed a separate 1-for-30 reverse split on November 6, 2026; 983,408 shares were outstanding as of November 16, 2026. A later split would leave 210 million authorized common shares unchanged. The company says a split may reduce trading liquidity or create odd lots, and it cannot assure the post-split price would stay above $1.00 or prevent delisting for other reasons.
Filing Explained
If implemented, the split could leave some holders with only cash and end their stockholder status; no added-share issuance is currently planned.
The December 4, 2026 vote is pending; approval would let the board implement a split without another stockholder vote. The
The company says it has no current plans to issue those additional shares, although some underlie warrants and convertible notes; if issued, additional shares would reduce existing holders’ percentage ownership. The split itself would leave percentage ownership unchanged except for fractional-share treatment; a holder who ends up with no whole share would instead receive cash and cease to be a stockholder.
Key Figures
Key Terms
reverse stock split technical
minimum per share bid price requirement regulatory
odd lot technical
broker non-votes regulatory
beneficial ownership regulatory
recapitalization financial
Compensation Summary
- Approve a charter amendment authorizing one or more reverse stock splits, with an aggregate ratio not exceeding 1-for-1,000, subject to board discretion.
- Approve adjournment of the special meeting, if necessary, to solicit additional proxies for the reverse stock split proposal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What reverse split is ADGM proposing?
When could ADGM carry out the proposed reverse split?
Would ADGM’s authorized shares change in a reverse split?
How would ADGM handle fractional shares in a reverse split?
AI-generated analysis. How Rhea-AI works. Not financial advice.
TABLE OF CONTENTS
☐ | Preliminary Proxy Statement |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☒ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material under §240.14a-12 |
Adagio Medical Holdings, Inc. |
(Name of Registrant as Specified in Its Charter) |
(Name of Person(s) Filing Proxy Statement if other than the Registrant) |
☒ | No fee required |
☐ | Fee paid previously with preliminary materials |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
TABLE OF CONTENTS

To approve an amendment to our Amended and Restated Certificate of Incorporation to effect, at the discretion of our Board of Directors, a reverse stock split of our common stock at a ratio of up to 1-for-1,000, which reverse stock split may be implemented on one or more occasions, when and as needed, to allow the Company to maintain compliance with Nasdaq listing requirements, with the exact stock split ratio or ratios to be determined by the Board of Directors in its sole discretion, provided that the aggregate splits will not exceed 1-for-1,000. We refer to this proposal as the “Reverse Stock Split Proposal” or “Proposal No. 1”.
To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal No. 1. We refer to this proposal as the “Adjournment Proposal” or “Proposal No. 2”.
To conduct any other business properly brought before the meeting.
By Order of the Board of Directors | |||
/s/ Deborah Kaster | |||
Deborah Kaster Chief Financial Officer and Chief Business Officer Laguna Hills, CA November 20, 2026 | |||
TABLE OF CONTENTS
Page | |||
PROXY STATEMENT | 1 | ||
PROPOSAL NO. 1 - APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF OUR COMMON STOCK | 6 | ||
PROPOSAL NO. 2 - APPROVAL OF THE ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES | 16 | ||
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 17 | ||
OTHER INFORMATION FOR STOCKHOLDERS | 19 | ||
OTHER MATTERS | 20 | ||
ANNEX A | A-1 | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Proposal No. 1 - To approve an amendment to our Amended and Restated Certificate of Incorporation to effect, at the discretion of our Board of Directors, a reverse stock split of our common stock at a ratio of up to 1-for-1,000, which reverse stock split may be implemented on one or more occasions, when and as needed, to maintain compliance with Nasdaq listing requirements, with the exact stock split ratio or ratios to be determined by the Board of Directors in its sole discretion, provided that the aggregate splits will not exceed 1-for-1,000. |
• | Proposal No. 2 - To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal No. 1. |
TABLE OF CONTENTS
By Internet | By Telephone | By Mail | During the Meeting | ||||||
You may vote your shares from any location in the world at www.proxyvote.com (you will need the control number printed on your proxy card). | You may vote your shares by calling 1-800-690-6903 and following the instructions on your proxy card. | If you received a proxy card by mail, you may vote by completing, dating and signing the proxy card and promptly mailing it in the postage-paid envelope provided. | To vote at the meeting, visit www.virtualshareholdermeeting. com/ADGM2026SM1 (you will need the control number printed on your proxy registration confirmation email). | ||||||
TABLE OF CONTENTS
• | You may submit another properly completed proxy card with a later date. |
• | You may grant a subsequent proxy by telephone or through the internet. |
• | You may send a timely written notice that you are revoking your proxy to Adagio’s Corporate Secretary at 26051 Merit Circle, Suite 102, Laguna Hills, CA 92653. Such notice will be considered timely if it is received at the indicated address by the close of business on the business day one week preceding the date of the Special Meeting. |
• | You may attend the Special Meeting and vote online. Simply attending the Special Meeting will not, by itself, revoke your proxy. |
TABLE OF CONTENTS
Proposal | Page Number | Vote Required for Approval | Voting Options | Effect of Votes Withheld/ Abstentions, As Applicable | Effect of Broker Non-Votes | ||||||||||||
Proposal No. 1: Reverse Stock Split(1) | 6 | FOR votes from the holders of a majority of votes cast by stockholders entitled to vote on the matter | FOR, AGAINST or ABSTAIN | No effect | Not applicable | ||||||||||||
Proposal No. 2: Adjournment Proposal(1) | 16 | FOR votes from the holders of a majority of votes cast by stockholders entitled to vote on the matter | FOR, AGAINST or ABSTAIN | No effect | Not applicable | ||||||||||||
(1) | This proposal is considered to be a “routine” matter under NYSE rules. Accordingly, if you hold your shares in street name and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority to vote your shares on this proposal. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | our ability to maintain the listing of our common stock on The Nasdaq Capital Market; |
• | the per share price of our common stock immediately prior to a Reverse Stock Split; |
• | the expected stability of the per share price of our common stock following a Reverse Stock Split; |
• | the likelihood that a Reverse Stock Split will result in increased marketability and liquidity of our common stock; |
• | prevailing market conditions; |
• | general economic conditions in our industry; and |
• | our market capitalization before and after a Reverse Stock Split. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | The reduced number of shares of our common stock resulting from a Reverse Stock Split could adversely affect the liquidity of our common stock. |
• | The Reverse Stock Split could result in a significant devaluation of our market capitalization and the trading price of our common stock, on an actual or an as-adjusted basis, based on the experience of other companies that have effected reverse stock splits. |
• | The Reverse Stock Split may leave certain stockholders with one or more “odd lots,” which are stock holdings in amounts of less than 100 shares of our common stock. These odd lots may be more difficult to sell than shares of common stock in even multiples of 100. Additionally, any reduction in brokerage commissions resulting from a Reverse Stock Split may be offset, in whole or in part, by increased brokerage commissions required to be paid by stockholders selling odd lots created by a Reverse Stock Split. |
• | There can be no assurance that the market price per new share of our common stock after a Reverse Stock Split will increase in proportion to the reduction in the number of old shares of our common stock outstanding before a Reverse Stock Split. For example, based on the closing market price of our common stock on November 18, 2026, of $1.52 per share of common stock, if the stockholders approve this proposal and the Board of Directors selects and implements a Reverse Stock Split ratio of 1-for-100, there can be no assurance that the post-split market price of our common stock would be $152.00 per share or greater. Accordingly, the total market capitalization of our common stock after the proposed Reverse Stock Split may be lower than the total market capitalization before the proposed Reverse Stock Split and, in the future, the market price of our common stock following a Reverse Stock Split may not exceed or remain higher than the market price prior to the proposed Reverse Stock Split. |
• | While the Board of Directors believes that a higher stock price may help generate investor interest, there can be no assurance that a Reverse Stock Split will result in a per share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our common stock may not necessarily improve. |
• | If a Reverse Stock Split is effected and the market price of our common stock declines, the percentage decline may be greater than would occur in the absence of a Reverse Stock Split. The market price of our common stock will, however, also be based on our performance and other factors, which are unrelated to the number of shares outstanding. |
TABLE OF CONTENTS
• | an individual who is a citizen or resident of the United States or treated as a U.S. citizen or resident for U.S. federal income tax purposes; |
• | a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; |
• | an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or |
• | a trust if (i) a U.S. court can exercise primary supervision over the trust’s administration and one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code) are authorized or have the authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Name and Address of Beneficial Owners(1) | Number of Shares | % | ||||
Current Executive Officers and Directors | ||||||
James L. Cox(2) | 16,272 | 1.63 | ||||
Deborah Kaster(3) | 15,883 | 1.59 | ||||
Sandra Gardiner(4) | 2,916 | * | ||||
Keyvan Mirsaeedi-Farahani(5) | 3,341 | * | ||||
Orly Mishan(6) | 9,721 | * | ||||
Timothy Moran(7) | 2,916 | * | ||||
Sean Salmon(8) | 1,500 | * | ||||
Todd Usen(9) | 38,517 | 3.79 | ||||
All current directors and executive officers as a group (eight individuals)(10) | 91,066 | 8.55 | ||||
Former Executive Officers | ||||||
Hakon Bergheim | 251 | * | ||||
Five Percent Holders | ||||||
Entities affiliated with Perceptive Advisors LLC(11) | 510,719 | 43.84 | ||||
Alyeska Master Fund, L.P.(12) | 86,123 | 8.35 | ||||
* | Less than 1% |
(1) | This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, the Company believes that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. The business address of each beneficial owner, unless otherwise stated, is 26051 Merit Circle, Suite 102, Laguna Hills, CA 92653. |
(2) | Consists of (a) 1,233 shares of common stock and (b) 15,049 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(3) | Consists of (a) 500 shares of common stock and (b) 15,383 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(4) | Consists of 2,916 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(5) | Consists of (a) 425 shares of common stock and (b) 2,916 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(6) | Consists of 9,721 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(7) | Consists of 2,916 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(8) | Consists of 1,500 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(9) | Consists of (a) 6,910 shares of common stock and (b) 31,607 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
(10) | Consists of (a) 9,058 shares of common stock and (b) 82,008 shares of common stock issuable upon exercise of options exercisable within 60 days of November 16, 2026. |
TABLE OF CONTENTS
(11) | Consists of (i) 322,521 shares of common stock directly held by Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”), (ii) warrants directly held by the Master Fund exercisable into 181,502 shares of common stock, and (iii) 6,696 shares of common stock directly held by C2 Life Sciences LLC (“C2”). Such amounts do not include shares of common stock issuable upon exercise of pre-funded warrants and warrants that may not be exercised if the aggregate number of shares of common stock beneficially owned by entities affiliated with the Master Fund would exceed 9.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such exercise. Perceptive Advisors LLC (the “Advisor”) serves as the investment manager of the Master Fund and C2. Joseph Edelman serves as the managing member of the Advisor. Accordingly, the Advisor and Mr. Edelman have voting and investment discretion with respect to, and may be deemed to beneficially own, the shares of common stock and warrants held of record by the Master Fund and C2. The Advisor does not directly hold any shares of common stock or warrants. The principal business address of each of these persons and entities is 51 Astor Place, 10th Floor, New York, NY 10003. |
(12) | Consists of (i) 38,653 shares of common stock and (ii) milestone warrants exercisable into 47,470 shares of common stock, in each case held by Alyeska Master Fund, L.P. Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P., has voting and investment control of the shares held by Alyeska Master Fund, L.P. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr. Parekh, however, disclaims any beneficial ownership of the shares held by Alyeska Master Fund, L.P. The registered address of Alyeska Master Fund, L.P. is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street, George Town, Grand Cayman, KY1-1104, Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago, IL 60601. |
TABLE OF CONTENTS
TABLE OF CONTENTS
By Order of the Board of Directors | |||
/s/ Deborah Kaster | |||
Deborah Kaster | |||
Chief Financial Officer and Chief Business Officer | |||
November 20, 2026 | |||
TABLE OF CONTENTS
1. | The name of the corporation is Adagio Medical Holdings, Inc. (the “Corporation”). |
2. | The Corporation’s original Certificate of Incorporation was filed on December 19, 2023. The Certificate of Incorporation was last amended and restated by the Amended and Restated Certificate of Incorporation on July 29, 2024, and further amended by a Certificate of Amendment on November 6, 2026 (together, the “Certificate”). |
3. | The Corporation’s Board of Directors and stockholders, acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions approving that Article IV of the Certificate be amended by replacing Section 6 of Article IV in its entirety with the following: |
4. | All other provisions of the Certificate will remain in full force and effect. |
5. | This Certificate of Amendment has been duly adopted in accordance with the provisions of Section 242 of the DGCL. |
6. | This Certificate of Amendment shall be effective on and as of the effective time of 5:00 p.m., Eastern Time, on [ ], 202[ ]. |
TABLE OF CONTENTS
Adagio Medical Holdings, Inc. | ||||||
By: | ||||||
Name: | Todd Usen | |||||
Title: | Chief Executive Officer | |||||
TABLE OF CONTENTS

TABLE OF CONTENTS
